CooperCompanies, a leading global medical device company, operates primarily through two divisions: CooperVision, which specializes in contact lenses, and CooperSurgical, which focuses on fertility and women’s healthcare. The company reported consolidated revenues of $1.002 billion for the second quarter of fiscal 2025, marking a year-over-year increase of 6% or 7% on an organic basis. CooperVision’s revenue comprised $670 million, reflecting a 5% reported increase, while CooperSurgical achieved $333 million, representing an 8% increase.

Key financial metrics include a gross margin of 68%, improved from 67.3% in the prior year, and a non-GAAP earnings per share (EPS) of $0.96, which is 14% higher than the same quarter last year. Operating margin also saw a rise, improving to 24.9%. Operating income was reported at $249.5 million, up from $224.8 million year-over-year. The company reported a net income of $87.7 million, with interest expenses decreasing to $23.5 million from $28.9 million a year ago.

Guidance for fiscal year 2025 has been adjusted to reflect updated expectations. Total revenue is now projected to be between $4.107 billion and $4.146 billion, with CooperVision’s revenue forecast set at $2.76 billion to $2.79 billion, indicating organic growth expectations of 6% to 7%. CooperSurgical’s revenue guidance ranges from $1.35 billion to $1.36 billion, with organic growth expectations adjusted to 3.5% to 4.5%. The company increased its EPS guidance to a range of $4.05 to $4.11, signaling a year-over-year growth expectation of approximately 10% to 11.5%.

CooperVision experienced particularly strong organic growth in several categories, with daily silicone hydrogel lenses growing by 10%. Geographically, the Americas saw an 8% growth, with EMEA and Asia Pacific growing by 6% and 5%, respectively. CooperSurgical’s office and surgical segment reflected robust performance with a 13% increase in revenue. Despite some market softness in fertility, particularly in Asia Pacific, overall growth factors remain intact.

The company repurchased approximately 537,000 shares at a cost of $40.6 million during the quarter, with $215.8 million remaining under its repurchase program. Additionally, free cash flow for the quarter was $18 million, following capital expenditures of $78.1 million. Net debt increased slightly to $2.47 billion, with a bank-defined leverage ratio of 1.9x.

For the upcoming quarter, CooperCompanies anticipates stronger organic growth rates compared to the second quarter, aligning with the expected launch rollout of new product lines.